LU90396I2 - Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable - Google Patents

Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable

Info

Publication number
LU90396I2
LU90396I2 LU90396C LU90396C LU90396I2 LU 90396 I2 LU90396 I2 LU 90396I2 LU 90396 C LU90396 C LU 90396C LU 90396 C LU90396 C LU 90396C LU 90396 I2 LU90396 I2 LU 90396I2
Authority
LU
Luxembourg
Prior art keywords
group
stands
alkoxy
alkyl
rabeprazole
Prior art date
Application number
LU90396C
Other languages
English (en)
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27283658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90396(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of LU90396I2 publication Critical patent/LU90396I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU90396C 1986-11-13 1999-05-07 Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable LU90396I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27053686 1986-11-13
JP2198987 1987-02-02
JP7778487 1987-03-31

Publications (1)

Publication Number Publication Date
LU90396I2 true LU90396I2 (fr) 1999-07-07

Family

ID=27283658

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90396C LU90396I2 (fr) 1986-11-13 1999-05-07 Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable

Country Status (18)

Country Link
US (3) US5045552A (fr)
EP (3) EP0475456B1 (fr)
JP (1) JP2544567B2 (fr)
KR (1) KR910003330B1 (fr)
CN (1) CN1018923B (fr)
AT (2) ATE168111T1 (fr)
AU (1) AU594836B2 (fr)
CA (1) CA1265138A (fr)
DE (4) DE3789536T3 (fr)
DK (2) DK171024B1 (fr)
ES (3) ES2112260T3 (fr)
FI (1) FI90544C (fr)
HK (1) HK194296A (fr)
HU (1) HU198475B (fr)
LU (1) LU90396I2 (fr)
NL (1) NL990015I2 (fr)
NO (2) NO170932C (fr)
NZ (1) NZ222488A (fr)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201884A (ja) * 1986-02-28 1987-09-05 Tokyo Tanabe Co Ltd ベンズイミダゾール誘導体及びその製造法
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
AT391693B (de) * 1988-11-15 1990-11-12 Cl Pharma Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
US5294629A (en) * 1988-11-22 1994-03-15 Meiji Seika Kaisha, Ltd. Benzothiazole and benzimidazole derivatives and antiulcer agent containing the same
EG19302A (en) * 1988-12-22 1994-11-30 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
ES2024357A6 (es) * 1990-12-05 1992-02-16 Genesis Para La Investigacion Procedimiento de obtencion de halohidrato de 2-halometil-3,5-dimetil-4-metoxipiri-dina.
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
EP0585722B1 (fr) * 1992-08-21 1996-05-15 Eisai Co., Ltd. Dérivés de benzimidasoles comme agent antibiotique contre le campylobacter pylÔne
JPH08507054A (ja) * 1993-02-17 1996-07-30 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング ヘリコバクターバクテリアに対抗するための置換されたヘテロアリールアルキルチオピリジン
UA32583C2 (uk) * 1993-06-29 2001-02-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх Похідні арилтіоалкілтіопіридину
TW280770B (fr) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
KR960705811A (ko) * 1993-10-29 1996-11-08 고오야 다다시 피리딘 화합물 및 그의 약학적 용도[pyridine compound and medicinal use thereof]
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
EP0983263A1 (fr) * 1997-05-30 2000-03-08 Dr. Reddy's Research Foundation Nouveaux benzimidazoles utilises comme agents antiulcereux, leur procede de preparation et compositions pharmaceutiques les contenant
WO1999004816A1 (fr) 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteur de la pompe a protons en combinaison therapeutique avec des substances antibacteriennes
US7230014B1 (en) 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
AU1361399A (en) * 1997-10-14 1999-05-03 Eisai Co. Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
WO1999036422A1 (fr) 1998-01-14 1999-07-22 The Uab Research Foundation Procede de synthese et de criblage d'inhibiteurs d'enzyme synthetase nad bacterienne, composes a base de cette enzyme et procedes de traitement des infections bacteriennes et microbiennes au moyen d'inhibiteurs de ladite enzyme
DE19815634A1 (de) * 1998-04-07 1999-10-14 Bayer Ag Verfahren zur Herstellung von 3-Methoxy-1-propanol
EP1073333A4 (fr) * 1998-04-30 2005-06-15 Sepracor Inc Compositions a base de s-rabeprazole et procedes
WO1999055157A1 (fr) * 1998-04-30 1999-11-04 Sepracor Inc. Compositions a base de r-rabeprazole et procedes
WO2000000474A1 (fr) * 1998-06-26 2000-01-06 Russinsky Limited Blocs constitutifs de pyrimidine utilises comme intermediaires dans la synthese de composes pharmaceutiquement actifs
YU10101A (sh) 1998-08-10 2003-10-31 Partnership Of Michael E. Garst George Sachs And Jai Moo Shin Prolekovi inhibitori proton pumpe
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
PT1105105E (pt) 1998-08-12 2006-07-31 Altana Pharma Ag Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
DE60021570T2 (de) 1999-06-07 2006-05-24 Altana Pharma Ag Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
WO2001074810A2 (fr) * 2000-03-31 2001-10-11 Ortho Mcneil Pharmaceutical, Inc. Procede d'utilisation de 2-aryloxyalkylaminobenzoxazoles et de 2-aryloxyalkylaminobenzothiazoles comme antagonistes vis-a-vis du recepteur h3
EP1359912A4 (fr) * 2000-06-19 2006-05-03 Eisai Co Ltd Nouvelles methodes utilisant des derives de pyridine
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (fr) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Formulation d'inhibiteur de la pompe à protons
DK1341528T3 (da) 2000-12-07 2012-03-26 Nycomed Gmbh Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel
US7988999B2 (en) 2000-12-07 2011-08-02 Nycomed Gmbh Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
BR0115989A (pt) 2000-12-07 2004-01-13 Altana Pharma Ag Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
NL1018295C2 (nl) * 2001-06-15 2002-12-17 Dsm Nv Werkwijze voor de bereiding van 4-chloor-pyridine-n-oxiden.
CN1243749C (zh) * 2001-09-18 2006-03-01 泽里新药工业株式会社 苯并咪唑衍生物
AU2002365936A1 (en) * 2001-11-16 2003-09-02 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
EP1487820A1 (fr) * 2002-03-26 2004-12-22 Dr. Reddy's Laboratories Ltd. Formes cristallines de rabeprazole sodique
AU2003241464A1 (en) * 2002-05-17 2003-12-02 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
AU2003254282A1 (en) * 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
AT413538B (de) * 2002-10-01 2006-03-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten pyridin-n-oxid-verbindungen
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
PL375818A1 (en) 2002-12-06 2005-12-12 Altana Pharma Ag Process for preparing optically pure active compounds
CA2507889C (fr) 2002-12-06 2012-02-07 Altana Pharma Ag Procede de preparation de (s)-pantoprazole
AR046245A1 (es) * 2002-12-16 2005-11-30 Ranbaxy Lab Ltd Sales de calcio de rabeprazol
CA2510849A1 (fr) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd Etats solides de sodium de pantoprazole, leurs procedes de preparation et procedes de preparation d'hydrates de sodium de pantoprazole connus
EP1583507A2 (fr) * 2003-01-07 2005-10-12 Ranbaxy Laboratories Limited Sels de magnesium de derives de l'imidazole
US20040180935A1 (en) * 2003-02-28 2004-09-16 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Inc. Crystalline form Z of rabeprazole sodium and process for preparation thereof
EP1601667A2 (fr) * 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Formes solides cristallines et amorphes de pantoprazole et procedes de preparation de ces formes
JP4355703B2 (ja) * 2003-03-13 2009-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 歯ぎしりの予防剤または治療剤
EP1607395B1 (fr) * 2003-03-24 2011-05-04 Eisai R&D Management Co., Ltd. Procédé de préparation de sel de sodium de rabeprazole amorphe
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US7524837B2 (en) * 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
EP1615913A2 (fr) * 2003-06-10 2006-01-18 Teva Pharmaceutical Industries Limited Procede de preparation de benzimidazoles 2- (pyridinyl)methyl]sulfinyle substitues et nouveau derives chlorures de pantoprazole
CA2529984C (fr) * 2003-06-26 2012-09-25 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
WO2005016917A1 (fr) * 2003-07-15 2005-02-24 Allergan, Inc. Procede de preparation de promedicaments isomeriquement purs d'inhibiteurs de la pompe a protons
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007504261A (ja) * 2003-09-03 2007-03-01 エイジーアイ・セラピューティクス・リサーチ・リミテッド プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005039640A1 (fr) * 2003-10-03 2005-05-06 Allergan Inc. Compositions contenant des peptides en trefle et/ou des mucoadhesifs et des promedicaments d'un inhibiteur de pompe a proton
EP1716136A1 (fr) 2004-02-11 2006-11-02 Ulkar Kimya Sanayii Ve Ticaret A.S. Pyridine benzimidazole sulphoxides de grande pureté
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
AU2005216862A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
CA2561700A1 (fr) * 2004-04-16 2005-12-15 Santarus, Inc. Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
JP2007536349A (ja) * 2004-05-07 2007-12-13 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の医薬剤形及び製造方法
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP4884967B2 (ja) * 2004-06-30 2012-02-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール誘導体塩沈殿物の製造方法
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006013960A1 (fr) * 2004-08-06 2006-02-09 Eisai R & D Management Co., Ltd. Sels de derive de benzimidazole avec des amines et procede de production de ceux-ci
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006024890A1 (fr) * 2004-08-30 2006-03-09 Apollo International Limited Procede ameliore de preparation de rabeprazole sodique sous forme amorphe
WO2006034632A1 (fr) * 2004-09-30 2006-04-06 Jiangsu Hansen Pharmaceutical Co., Ltd. Nouveau compose prazole et son utilisation
CN100364989C (zh) * 2004-09-30 2008-01-30 江苏豪森药业股份有限公司 拉唑类衍生物及其盐和用途
EP2417986A1 (fr) 2004-11-22 2012-02-15 Anadis Ltd. Compositions bioactives
NZ561008A (en) * 2005-02-21 2009-09-25 Cipla Ltd New process for synthesis of proton pump inhibitors, namely Rabeprazole sodium
WO2006120701A1 (fr) * 2005-03-30 2006-11-16 Lupin Limited Procede perfectionne de fabrication de rabeprazole sodium
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1818331A1 (fr) 2006-02-14 2007-08-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Procédé pour la préparation de 2-[{4-(3-méthoxypropoxy)-3-méthyl-2-pyridinyl}méthylsulfinyl]-1H-benzimidazole essentiellement exempte d'impurité sulfone
SI2003130T1 (sl) * 2006-03-10 2012-02-29 Arigen Pharmaceuticals Inc Nov piridinski derivat, ki ima aktivnost proti Helicobacter pylori
EP2007360B1 (fr) 2006-04-03 2014-11-26 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
KR100771655B1 (ko) * 2006-04-24 2007-10-30 주식회사 카이로제닉스 라베프라졸 및 그 중간체의 제조방법
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US7786309B2 (en) 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
WO2008017020A2 (fr) * 2006-08-03 2008-02-07 Dr. Reddy's Laboratories Limited Procédé de preparation d'inhibiteurs de la pompe à protons
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
CA2665226C (fr) 2006-10-05 2014-05-13 Santarus, Inc. Nouvelles formulations pour une liberation immediate d'inhibiteurs de pompe a protons et procedes d'utilisation de ces formulations
WO2008047681A1 (fr) * 2006-10-13 2008-04-24 Eisai R & D Management Co., Ltd. Benzimidazole présentant une activité inhibitrice de la sécrétion d'acide gastrique
CA2667682A1 (fr) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprenant des agents d'inhibition de la pompe a protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procedes d'utilisation
SI2103608T1 (sl) 2006-12-18 2012-12-31 Arigen Pharmaceuticals, Inc. Sredstvo za eradikacijo Helicobacterja pylori z inhibitorno aktivnostjo za izločanje želoldčne kisline
ITMI20062449A1 (it) 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
JP2010514702A (ja) 2006-12-22 2010-05-06 アイロンウッド ファーマシューティカルズ，インコーポレーテッド 食道障害の治療方法および治療用組成物
KR20090121388A (ko) * 2007-03-15 2009-11-25 썬 파마 어드밴스트 리서치 컴패니 리미티드 신규 전구약물
WO2008146297A2 (fr) * 2007-05-25 2008-12-04 Hetero Drugs Limited Procédé amélioré de preparation de rabéprazole sodique amorphe
WO2008155780A2 (fr) * 2007-06-21 2008-12-24 Matrix Laboratories Ltd Procédé perfectionné pour la préparation de rabéprazole pur
WO2009010937A1 (fr) * 2007-07-17 2009-01-22 Ranbaxy Laboratories Limited Procédé de préparation de pantoprazole sodique.
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
CN101497604B (zh) * 2008-01-30 2012-09-26 山东轩竹医药科技有限公司 含有被烷氧乙酰胺基氧基取代的吡啶的苯并咪唑衍生物
SI22806A (sl) * 2008-06-23 2009-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalinične oblike natrijevega rabeprazola
US20120041030A1 (en) 2009-04-09 2012-02-16 Masaichi Yamamoto Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-helicobacter pylori action
WO2010134099A1 (fr) 2009-05-21 2010-11-25 Cadila Healthcare Limited Procédé de préparation dans un récipient unique d'oméprazole
WO2011004281A1 (fr) 2009-07-09 2011-01-13 Alembic Limited Procédé pour la préparation d’une forme amorphe de rabéprazole sodium
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
WO2011121546A1 (fr) * 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Sels de dexlansoprazole et leur élaboration
CN102219777B (zh) * 2010-04-19 2013-06-05 江苏豪森药业股份有限公司 制备雷贝拉唑钠的方法
CN101805327B (zh) * 2010-04-29 2012-11-21 郝志艳 一种雷贝拉唑钠化合物及其制法
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
WO2013108068A1 (fr) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Procédé de préparation de 2-pyridinylméthylsulfinylbenzimidazoles, leurs analogues et énantiomères optiquement actifs
WO2014091450A1 (fr) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Procédé pour la préparation de rabéprazole
CN105338958A (zh) 2013-01-15 2016-02-17 铁木医药有限公司 胆汁酸螯合剂的胃内滞留缓释口服剂型
CN103073536B (zh) * 2013-01-17 2015-06-24 丽珠医药集团股份有限公司 一种艾普拉唑的制备方法
CN103709141A (zh) * 2013-10-14 2014-04-09 寿光富康制药有限公司 雷贝拉唑钠的晶型及无定形形式
CN104119315B (zh) * 2014-05-21 2016-03-02 丽珠医药集团股份有限公司 一种雷贝拉唑钠的制备方法
RU2554735C1 (ru) * 2014-08-20 2015-06-27 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая рабепразол натрия, и способ ее получения
WO2016126625A1 (fr) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Méthodes de traitement de troubles gastro-intestinaux supérieurs de gerd réfractaire à ppi
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106083705A (zh) * 2016-06-14 2016-11-09 上药康丽（常州）药业有限公司 2‑羟甲基‑4‑（甲氧基丙氧基）‑3‑甲基吡啶盐酸盐的制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106349220A (zh) * 2016-08-25 2017-01-25 岳阳正昊化学科技有限公司 一种右旋雷贝拉唑钠的纯化方法
JP7044789B2 (ja) 2016-09-24 2022-03-30 ワシントン・ユニバーシティ Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用
JP2022548785A (ja) 2019-09-24 2022-11-21 プロラクタ バイオサイエンス，インコーポレイテッド 炎症性疾患及び免疫疾患の治療のための組成物及び方法
WO2024075017A1 (fr) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition de calcification de valve aortique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
ZA825106B (en) * 1981-08-13 1983-04-27 Haessle Ab Novel pharmaceutical compositions
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
GB8417171D0 (en) * 1984-07-05 1984-08-08 Beecham Group Plc Compounds
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
DE3509333A1 (de) * 1985-03-15 1986-09-18 Hoechst Ag, 6230 Frankfurt Substituierte benzimidazolderivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
JPH0674272B2 (ja) * 1986-11-13 1994-09-21 エーザイ株式会社 ピリジン誘導体及びそれを含有する潰瘍治療剤
DE4036908A1 (de) * 1990-11-20 1992-05-21 Ruetgers Pagid Ag Nutausbildung

Also Published As

Publication number Publication date
DK171024B1 (da) 1996-04-22
DE3752201D1 (de) 1998-08-13
DE19975035I2 (de) 2004-01-29
EP0268956A3 (en) 1990-07-25
NO170932B (no) 1992-09-21
DE3752201T2 (de) 1998-12-17
KR880006229A (ko) 1988-07-22
DK575887D0 (da) 1987-11-03
NO170932C (no) 1992-12-30
NO874477D0 (no) 1987-10-27
ES2061471T5 (es) 1998-07-16
NO2000006I1 (no) 2000-09-18
FI90544C (fi) 1994-02-25
CA1265138A (fr) 1990-01-30
EP0268956B2 (fr) 1998-04-15
DE3789536T2 (de) 1994-08-18
HUT45524A (en) 1988-07-28
DK131893A (da) 1993-11-24
EP0475456A1 (fr) 1992-03-18
FI90544B (fi) 1993-11-15
CN87107777A (zh) 1988-06-01
FI874709A (fi) 1988-05-14
NL990015I2 (nl) 1999-09-01
US5840910A (en) 1998-11-24
DE3789536D1 (de) 1994-05-11
EP0654471B1 (fr) 1998-07-08
DE3789536T3 (de) 1998-08-20
ATE168111T1 (de) 1998-07-15
EP0268956B1 (fr) 1994-04-06
JP2544567B2 (ja) 1996-10-16
US5045552A (en) 1991-09-03
NL990015I1 (nl) 1999-08-02
ATE163011T1 (de) 1998-02-15
EP0268956A2 (fr) 1988-06-01
DE3752167T2 (de) 1998-06-25
AU8113887A (en) 1988-05-19
EP0475456B1 (fr) 1998-02-04
HU198475B (en) 1989-10-30
FI874709A0 (fi) 1987-10-26
DE3752167D1 (de) 1998-03-12
ES2061471T3 (es) 1994-12-16
HK194296A (en) 1996-11-01
ES2118457T3 (es) 1998-09-16
US5998445A (en) 1999-12-07
NO874477L (no) 1988-05-16
KR910003330B1 (ko) 1991-05-27
DK575887A (da) 1988-05-14
ES2112260T3 (es) 1998-04-01
EP0654471A1 (fr) 1995-05-24
CN1018923B (zh) 1992-11-04
AU594836B2 (en) 1990-03-15
DK131893D0 (da) 1993-11-24
NZ222488A (en) 1993-05-26
JPH05247035A (ja) 1993-09-24

Similar Documents

Publication Publication Date Title
LU90396I2 (fr) Pariet principeactif: rabeprazole sodique rabeprazole et tout autre de ces sels pharmaceutiquement acceptable
FI101193B (fi) Menetelmä N-£4-£5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3 -yyli-metyyli|-3-metoksibentsoyyli|-2-metyylibentseenisulfonamidin fys ikaalista muotoa sisältävän farmaseuttisen koostumuksen valmistamiseks i
CA2018960A1 (fr) Derives de la salicyladehyde et de l'acide salycilique et leurs analogues soufres, leur preparation et leur utilisation comme herbicides et bioregulateurs
EP0097323A3 (fr) Dérivés de 2-(4-pyridyl)-thiazole
IE810108L (en) IMIDAZO £1,2-a| PYRIDINES
MY109557A (en) Branched alkylamino derivatives of thiazole, processes for preparing them and pharmaceutical compositions containing them.
CS782686A2 (en) Method of benzimidazole derivatives production
HUP0001438A1 (hu) Új 2-(iminometil)aminofenil-származékok, előállításuk, alkalmazásuk gyógyászati készítmények előállítására, valamint az ezeket tartalmazó gyógyászati készítmények
MY101970A (en) Zwitterionic bicyclic compounds and their salts, solvates, hydrates and esters.
HUT57763A (en) Process for producing 2,9-disubstituted-4h-pyrido(1,2-a)pyrimidine-4-one derivatives and pharmaceutical compositions comprising such compounds as active ingredient
DK491489D0 (da) Imidazolinderivater samt fremgangsmaade til fremstilling deraf
RU93045711A (ru) Нейролептические пергидро-1h-пиридо(1,2-a)пиразины, способ их получения, фармацевтическая композиция, способ лечения
FR2458556B1 (fr)
DK0457090T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-(het)-aroyl-acrylsyrederivater
GR3026762T3 (en) Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same
NO923983L (no) Bisfenyletanderivater, fremgangsmaate for deres fremstilling og farmasoeytiske preparater derav
SE8300865D0 (sv) Mjoldrygealkaloider, forfarande for framstellning derav och dessa foreningar innehallande farmaceutiska kompositioner
ES8704477A1 (es) Procedimiento para preparar piridin-1-oxidos varias veces substituidos
FR2387979A1 (fr) Nouvelles 3-(thienyloxy) pyridines utiles comme medicaments et procedes pour leur preparation